A phase I/II study of tgAAV-CF for the treatment of chronic sinusitis in patients with cystic fibrosis

Hum Gene Ther. 1998 Apr 10;9(6):889-909. doi: 10.1089/hum.1998.9.6-889.

Authors

J A Wagner¹, M L Moran, A H Messner, R Daifuku, C K Conrad, T Reynolds, W B Guggino, R B Moss, B J Carter, J J Wine, T R Flotte, P Gardner

Affiliation

¹ Department of Molecular Pharmacology, Stanford University School of Medicine, CA 94305-5332, USA.

PMID: 9581911
DOI: 10.1089/hum.1998.9.6-889

No abstract available

Publication types

Clinical Trial
Clinical Trial, Phase I
Clinical Trial, Phase II
Randomized Controlled Trial

MeSH terms

Adolescent
Adult
Chronic Disease
Clinical Protocols
Cystic Fibrosis / complications
Cystic Fibrosis / therapy*
Cystic Fibrosis Transmembrane Conductance Regulator / genetics*
Cystic Fibrosis Transmembrane Conductance Regulator / therapeutic use*
Dependovirus / genetics
Female
Genetic Therapy*
Genetic Vectors
Humans
Male
Middle Aged
Sinusitis / complications
Sinusitis / therapy*

Substances

CFTR protein, human
Cystic Fibrosis Transmembrane Conductance Regulator